March 14, 2024
Japan’s health ministry on March 13 reported the results of cost-effectiveness assessments (CEAs) for MSD’s COVID-19 drug Lagevrio (molnupiravir) and Bayer Yakuhin’s chronic kidney disease (CKD) therapy Kerendia (finerenone), putting them in line for downward price tweaks. Lagevrio was granted...read more